Can Dr Reddy’s Carve Into Crowded Indian Avastin Biosimilar Market?

 
• By Anju Ghangurde

Dr Reddy’s debuts biosimilar bevacizumab in India but can the significant price differential for one strength of the product help it gnaw into a competitive market?

Leadership
Dr Reddy's Launches Cut-Price Biosimilar Avastin In India • Source: Shutterstock

More from Business

More from Scrip